12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Benzinga · 06/16 12:05
Gainers
- CervoMed (NASDAQ:CRVO) shares moved upwards by 24.2% to $3.08 during Tuesday's pre-market session. The company's market cap stands at $22.9 million.
- IM Cannabis (NASDAQ:IMCC) shares rose 18.77% to $0.31. The market value of their outstanding shares is at $2.3 million.
- High Tide (NASDAQ:HITI) shares rose 14.22% to $2.57. The company's market cap stands at $197.7 million. As per the news, the Q2 earnings report came out yesterday.
- Camp4 Therapeutics (NASDAQ:CAMP) stock increased by 13.63% to $4.5. The company's market cap stands at $205.6 million.
- Hyperliquid Strategies (NASDAQ:PURR) stock moved upwards by 12.41% to $10.5. The company's market cap stands at $1.3 billion.
- Lunai Bioworks (NASDAQ:LNAI) stock rose 11.49% to $2.91. The company's market cap stands at $11.8 million.
Losers
- PRF Technologies (NASDAQ:PRFX) stock declined by 30.1% to $1.74 during Tuesday's pre-market session. The company's market cap stands at $2.1 million.
- Cuprina Holdings (Cayman) (NASDAQ:CUPR) stock declined by 27.35% to $6.11. The company's market cap stands at $22.5 million.
- Scilex Holding (NASDAQ:SCLX) shares fell 21.39% to $6.25. The market value of their outstanding shares is at $55.9 million.
- Edgewise Therapeutics (NASDAQ:EWTX) shares decreased by 14.77% to $30.01. The market value of their outstanding shares is at $3.7 billion.
- YD Bio (NASDAQ:YDES) shares decreased by 14.46% to $2.9. The market value of their outstanding shares is at $240.1 million.
- SANUWAVE Health (NASDAQ:SNWV) shares decreased by 12.89% to $12.78. The company's market cap stands at $126.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.